^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Omisirge (omidubicel)

    i
    Associations
    News

    Trials

    Company:
    Ayrmid
    Drug class:
    Immunostimulant, Stem cell stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (NCT03173937)
    Phase 1/2
    National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/13/2017
    Primary completion :
    04/28/2025
    Completion :
    03/01/2028
    CD34 • HLA-B • HLA-C
    |
    Omisirge (omidubicel)
    Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCI-2017-02205) (NCT03399773)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/10/2022
    Primary completion :
    10/08/2024
    Completion :
    06/30/2026
    HLA-DRB1 • CD34 • HLA-B
    |
    cyclophosphamide • fludarabine IV • thiotepa • Omisirge (omidubicel) • cyclophosphamide intravenous • dilanubicel (DVX101)